Potential applications of nicotinic ligands in the laboratory and clinic

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 8, 2004, Pages 1837-1839

  Dani, J A ^a   De Biasi, M ^a   Liang, Y ^a   Peterson, J ^a   Zhang, L ^a   Zhang, T ^a   Zhou, F M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; ION CHANNEL; IVERMECTIN; NEUROTRANSMITTER; NICOTINIC RECEPTOR; POLYPEPTIDE; PRESYNAPTIC RECEPTOR; PROTEIN SUBUNIT;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE CELL; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; HUMAN; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NERVOUS SYSTEM; PRESYNAPTIC NERVE; SYNAPTOGENESIS;

ALZHEIMER DISEASE; ANIMALS; HUMANS; LIGANDS; MICE; MICE, KNOCKOUT; NEURONS; NICOTINIC AGONISTS; PROTEIN SUBUNITS; RECEPTORS, NICOTINIC; SUBSTRATE SPECIFICITY; SYNAPTIC TRANSMISSION;

EID: 1642634898     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.036     Document Type: Article

References (31)

1. Albuquerque E.X., Alkondon M., Pereira E.F., Castro N.G., Schrattenholz A., Barbosa C.T., Bonfante-Cabarcas R., Aracava Y., Eisenberg H.M., Maelicke A. J. Pharmacol. Exp. Ther. 280:1997;1117.
2. Dani J.A. Biol. Psychiatry. 49:2001;166.
3. Dani J.A., Ji D., Zhou F.M. Neuron. 31:2001;349.
4. Dani J.A., De Biasi M. Pharm. Biochem. Behav. 70:2001;439.
5. Jones S., Sudweeks S., Yakel J.L. Trends Neurosci. 22:1999;555.
6. Lena C., Changeux J.P. J. Physiol. Paris. 92:1998;63.
7. Lindstrom J. Mol. Neurobiol. 15:1997;193.
8. Luetje C.W., Patrick J., Séguéla P. FASEB J. 4:1990;2753.
9. McGehee D.S., Role L.W. Annu. Rev. Physiol. 57:1995;521.
10. Paterson D., Nordberg A. Prog. Neurobiol. 61:2000;75.
11. Role L.W., Berg D.K. Neuron. 16:1996;1077.
12. Wonnacott S. Trends Neurosci. 20:1997;92.
13. Dani J.A., Radcliffe K.A., Pidoplichko V.I. Eur. J. Pharmacol. 393:2000;31.
14. Fenster C.P., Hicks J.H., Beckman M.L., Covernton P.J., Quick M.W., Lester R.A. Ann N. Y. Acad. Sci. 868:1999;620.
15. Miyazawa A., Fujiyoshi Y., Unwin N. Nature. 423:2003;949.
16. Clarke P.B., Schwartz R.D., Paul S.M., Pert C.B., Pert A. J. Neurosci. 5:1985;1307.
17. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., Swanson L.W. J. Comp. Neurol. 284:1989;314.
18. Wada E., McKinnon D., Heinemann S., Patrick J., Swanson L.W. Brain Res. 526:1990;45.
19. Salas R., Orr-Urtreger A., Broide R.S., Beaudet A., Paylor R., De Biasi M. Mol. Pharmacol. 63:2003;1059.
20. Mansvelder H.D., McGehee D.S. J. Neurobiol. 53:2002;606.
21. McGehee D.S., Heath M.J., Gelber S., Devay P., Role L.W. Science. 269:1995;1692.
22. Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A. Nature. 383:1996;713.
23. Revah F., Bertrand D., Galzi J.L., Devillers-Thiery A., Mulle C., Hussy N., Bertrand S., Ballivet M., Changeux J.P. Nature. 353:1991;846.
24. Bertrand D., Devillers-Thiery A., Revah F., Galzi J.L., Hussy N., Mulle C., Bertrand S., Ballivet M., Changeux J.P. Proc. Natl. Acad. Sci. U.S.A. 89:1992;1261.
25. Ji D., Lape R., Dani J.A. Neuron. 31:2001;131.
26. Krause R.M., Buisson B., Bertrand S., Corringer P.J., Galzi J.L., Changeux J.P., Bertrand D. Mol. Pharmacol. 53:1998;283.
27. Pereira E.F., Hilmas C., Santos M.D., Alkondon M., Maelicke A., Albuquerque E.X. J. Neurobiol. 53:2002;479.
28. Fibiger H.C. Trends Neurosci. 14:1991;220.
29. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Nasland J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Eur. J. Pharmacol. 393:2000;215.
30. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X., Zerlin M. Biol. Psychiatry. 49:2001;279.
31. Maelicke A., Schrattenholz A., Samochocki M., Radina M., Albuquerque E.X. Behav. Brain Res. 113:2000;199.